Effects of Treatment of Recurrent/Refractory Medullablastoma/CNS PNET of Childhood

Children's Oncology Group (COG)


Clinical Trial

Offered by: Nemours
Locations: Delaware Valley, Jacksonville, FL, Orlando, FL, Pensacola, FL

Trial Name

Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial.

What is the trial about?

Effects of giving temozolomide together with irinotecan as well as adding bevacizumab to treatment with temozolomide and irinotecan has on people with recurrent or refractory medulloblastoma/PNET.

Who can participate?

Children who have been diagnosed with a medulloblastoma or PNET (Primitive Neuroectodermal Tumor) that is recurrent/refractory.

What is involved?

Length of participation dependent upon response to treatment. Standard cancer care.

Contact Nemours Clinical Trials

Trial Name: Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial

COG#: ACNS0821

Contact Information

(800) 354-5690
clinicaltrials@nemours.org